Stem cells offer new hope for type 1 treatmentMonday, 24 August 2020
An international research team has successfully derived insulin-producing pancreatic cells from stem cells and protected them from the body’s immune system. The development offers hope for improving treatments for type 1 diabetes.
In type 1 diabetes, the body turns on itself and attacks the beta cells in the pancreas called “islets”.
These beta cells are responsible for gauging glucose levels in the blood and releasing insulin to keep them stable. When they are depleted, a person is at risk for either high or low blood glucose and has to rely on insulin injections.
Transplanted islets often fail to connect with blood supply, and even when they do, like other transplants, they risk attack from the immune system of the recipient, which sees it as an invasion.
This means patients have to take drugs that suppress their immune systems, protecting their transplant but exposing the rest of their body to other illness.
To overcome some of these challenges, a team looked for another source of islets, by coaxing stem cells to produce what the team called HILOs, or human islet-like organoids.
These HILOs, when grown in a 3D environment mimicking the pancreas and then turbocharged with a “genetic switch”, successfully produced insulin and were able to regulate blood glucose function after being transplanted into diabetic mice.
Fending off immune attack
Having found a potential way to solve the supply chain problem, the scientists then sought to tackle the issue of immune rejection.
They focused on something called PD-L1, a kind of protein that is known to inhibit the body’s immune response.
When the team induced the HILOs to produce PD-L1, they were effectively able to “hide” the transplants from the body’s immune system, protecting them from attack.
They transplanted HILOs both with and without PD-L1 into mice with diabetes to test the function.
Initially both transplants restored control of blood glucose levels, but gradually, the unprotected HILOs stopped functioning.
But the HILOs with PD-L1 helped the mice regulate their blood glucose for more than 50 days.
“This is the first study to show that you can protect HILOs from the immune system without genetic manipulation,” said Michael Downes, senior staff scientist at the Salk Institute for Biological Studies and a co-author of the study published in the journal Nature.
“If we are able to develop this as a therapy, patients will not need to take immunosuppressive drugs,” he added.
It is estimated that more than 122,800 Australians are currently living with type 1 diabetes. Islet transplantation is generally considered as a treatment for the condition.
But while the prospect of individually grown islets derived from stem cells might appear an attractive solution, the study warns that is likely to be “prohibitively expensive.”
A more likely application of the research might be to use the PD-L1 protection method to allow successful transplants without the need for immunosuppressants, the authors wrote.